PIMA - Individualized Adherence Improvement Plan

计划入组 200 人 · 首次发布于 2020 年 12 月 2 日

Renoprotection in Early Diabetic Nephropathy in Pima Indians

计划入组 170 人 · 首次发布于 2006 年 6 月 21 日

Delaying the Progression of Diabetic Nephropathy in Pima Indians

计划入组 25 人 · 首次发布于 2006 年 7 月 18 日

Lusutrombopag(Mulpleta, Mulpleo (previously Lusutrombopag Shionogi))

C₂₉H₃₂Cl₂N₂O₅S · Rx

Avatrombopag(Doptelet 60 Mg Daily Dose Carton, Doptelet)

C₂₉H₃₄Cl₂N₆O₃S₂ · Rx

Chlorotrianisene

C₂₃H₂₁ClO₃

RIMA OBEID

Australia

Puma Biotechnology

United States

Prima Biomed

Australia

Aqua Medical Advances PIMA Procedure for Type 2 Diabetes with First West Coast Patient and New CEO

Aqua Medical Receives FDA IDE Approval for Breakthrough Endoscopic Type 2 Diabetes Treatment

CVRx's Barostim Receives Medicare Payment Boost, Enhancing Patient Access